MétaCan
Menu
Back to cohort
Record W2939763242 · doi:10.1093/sleep/zsz067.599

0601 Long-term Effects Of Solriamfetol On Quality Of Life In Participants With Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

2019· article· en· W2939763242 on OpenAlexaff
Terri E. Weaver, Jean‐Louis Pépin, Richard J. Schwab, Colin M. Shapiro, Jan Hedner, Mansoor Ahmed, Nancy Foldvary‐Schaefer, Patrick J. Strollo, Geert Mayer, Kathleen Sarmiento, Michelle Baladi, Morgan Bron, Patricia Chandler, Lawrence Lee, Atul Malhotra

Bibliographic record

VenueSLEEP · 2019
Typearticle
Languageen
FieldNeuroscience
TopicSleep and Wakefulness Research
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsNarcolepsyObstructive sleep apneaMedicineExcessive daytime sleepinessQuality of life (healthcare)PopulationPhysical therapySleep disorderSleep apneaEpworth Sleepiness ScalePolysomnographyInternal medicineInsomniaApneaPsychiatryModafinil

Abstract

fetched live from OpenAlex

Solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor, demonstrated long-term (up to 52 weeks) efficacy in participants with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). These analyses evaluated long-term effects of solriamfetol on quality of life (QoL) measures. Participants with narcolepsy or OSA who completed previous solriamfetol studies were eligible. This study included 2-week titration followed by a maintenance phase of up to 50 weeks (stable dose 75, 150, or 300 mg). QoL assessments included the Functional Outcomes of Sleep Questionnaire short version (FOSQ-10), Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP), and 36-Item Short Form Health Survey version 2 (SF-36v2). Mean (SD) change from baseline throughout the study was evaluated for the overall safety population and by subgroup (OSA or narcolepsy). No formal statistical testing was performed. Safety was assessed. There were 643 participants (417 OSA, 226 narcolepsy) in the safety population. Increases in mean FOSQ-10 total score from baseline [mean change (SD) of 3.7 (3.0)] were sustained for the duration of treatment with solriamfetol; magnitude of change was similar between narcolepsy and OSA. On WPAI:SHP, participants reported a minimum 25% reduction (improvement) from baseline for % activity impairment outside of work, % impairment while working (presenteeism), and % overall work impairment due to the problem; results were generally similar for each subgroup. For SF-36v2, both physical and mental component summary scores showed increases in the health state of participants from baseline [mean change (SD) of 3.1 (6.9) and 4.3 (8.4), respectively]; these improvements were maintained for the duration of the study. Common adverse events (≥5%) included headache, nausea, insomnia, nasopharyngitis, dry mouth, anxiety, decreased appetite, and upper-respiratory-tract infection, and were similar in narcolepsy and OSA; 27 participants (4.2%) had ≥1 serious adverse event. Solriamfetol demonstrated sustained improvements in QoL measures for up to 52 weeks in participants with EDS associated with narcolepsy or OSA. Safety was similar to prior solriamfetol studies. Jazz Pharmaceuticals

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.326
Teacher spread0.278 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueSLEEPSame topicSleep and Wakefulness ResearchFrench-language works237,207